{"id":822045,"date":"2025-03-05T09:28:15","date_gmt":"2025-03-05T14:28:15","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-present-at-the-37th-annual-roth-conference\/"},"modified":"2025-03-05T09:28:15","modified_gmt":"2025-03-05T14:28:15","slug":"longeveron-to-present-at-the-37th-annual-roth-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-present-at-the-37th-annual-roth-conference\/","title":{"rendered":"Longeveron\u00ae to Present at the 37th Annual Roth Conference"},"content":{"rendered":"
\n

MIAMI, March 05, 2025 (GLOBE NEWSWIRE) — Longeveron Inc.<\/a> (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in the 37th<\/sup> Annual Roth Conference taking place March 17-18, 2025.<\/p>\n

Details for the Company\u2019s fireside chat:<\/p>\n\n\n\n
\u00a0<\/td>\nDate:<\/td>\nTuesday, March 18, 2025<\/td>\n<\/tr>\n
\u00a0<\/td>\nTime:<\/td>\n9:00 \u2013 9:25 a.m. PT<\/td>\n<\/tr>\n<\/table>\n

\n
The webcast for this conference presentation may be accessed at the \u201cEvents and Presentations<\/a>\u201d section of the Company\u2019s website. A replay of the webcast will be available on the Longeveron website for 90 days following the conference.<\/p>\n

\n About Longeveron Inc.<\/strong>\n <\/p>\n

Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company\u2019s lead investigational product is Lomecel-B\u2122, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B\u2122 has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer\u2019s disease, and Aging-related Frailty. Lomecel-B\u2122\u00a0development programs have received five distinct and important FDA designations: for the HLHS program \u2013 Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program \u2013 Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com<\/a> or follow Longeveron on LinkedIn<\/a>, X<\/a>, and Instagram<\/a>.<\/p>\n

\n Investor and Media Contact:<\/strong>
\n
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

MIAMI, March 05, 2025 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in the 37th Annual Roth Conference taking place March 17-18, 2025. Details for the Company\u2019s fireside chat: \u00a0 Date: Tuesday, March 18, 2025 \u00a0 Time: 9:00 \u2013 9:25 a.m. PT The webcast for this conference presentation may be accessed at the \u201cEvents and Presentations\u201d section of the Company\u2019s website. A replay of the webcast will be available on the Longeveron website for 90 days following the conference. About Longeveron Inc. Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company\u2019s … <\/p>\n

Continue reading “Longeveron\u00ae to Present at the 37th Annual Roth Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-822045","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nLongeveron\u00ae to Present at the 37th Annual Roth Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-present-at-the-37th-annual-roth-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Longeveron\u00ae to Present at the 37th Annual Roth Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MIAMI, March 05, 2025 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in the 37th Annual Roth Conference taking place March 17-18, 2025. Details for the Company\u2019s fireside chat: \u00a0 Date: Tuesday, March 18, 2025 \u00a0 Time: 9:00 \u2013 9:25 a.m. PT The webcast for this conference presentation may be accessed at the \u201cEvents and Presentations\u201d section of the Company\u2019s website. A replay of the webcast will be available on the Longeveron website for 90 days following the conference. About Longeveron Inc. Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company\u2019s … Continue reading "Longeveron\u00ae to Present at the 37th Annual Roth Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-present-at-the-37th-annual-roth-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-05T14:28:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4ODg3MiM2NzkwMzYxIzIyMDcwNjA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-to-present-at-the-37th-annual-roth-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-to-present-at-the-37th-annual-roth-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Longeveron\u00ae to Present at the 37th Annual Roth Conference\",\"datePublished\":\"2025-03-05T14:28:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-to-present-at-the-37th-annual-roth-conference\\\/\"},\"wordCount\":259,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-to-present-at-the-37th-annual-roth-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4ODg3MiM2NzkwMzYxIzIyMDcwNjA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-to-present-at-the-37th-annual-roth-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-to-present-at-the-37th-annual-roth-conference\\\/\",\"name\":\"Longeveron\u00ae to Present at the 37th Annual Roth Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-to-present-at-the-37th-annual-roth-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-to-present-at-the-37th-annual-roth-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4ODg3MiM2NzkwMzYxIzIyMDcwNjA=\",\"datePublished\":\"2025-03-05T14:28:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-to-present-at-the-37th-annual-roth-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-to-present-at-the-37th-annual-roth-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-to-present-at-the-37th-annual-roth-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4ODg3MiM2NzkwMzYxIzIyMDcwNjA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4ODg3MiM2NzkwMzYxIzIyMDcwNjA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-to-present-at-the-37th-annual-roth-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Longeveron\u00ae to Present at the 37th Annual Roth Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Longeveron\u00ae to Present at the 37th Annual Roth Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-present-at-the-37th-annual-roth-conference\/","og_locale":"en_US","og_type":"article","og_title":"Longeveron\u00ae to Present at the 37th Annual Roth Conference - Market Newsdesk","og_description":"MIAMI, March 05, 2025 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in the 37th Annual Roth Conference taking place March 17-18, 2025. Details for the Company\u2019s fireside chat: \u00a0 Date: Tuesday, March 18, 2025 \u00a0 Time: 9:00 \u2013 9:25 a.m. PT The webcast for this conference presentation may be accessed at the \u201cEvents and Presentations\u201d section of the Company\u2019s website. A replay of the webcast will be available on the Longeveron website for 90 days following the conference. About Longeveron Inc. Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company\u2019s … Continue reading \"Longeveron\u00ae to Present at the 37th Annual Roth Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-present-at-the-37th-annual-roth-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-05T14:28:15+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4ODg3MiM2NzkwMzYxIzIyMDcwNjA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-present-at-the-37th-annual-roth-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-present-at-the-37th-annual-roth-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Longeveron\u00ae to Present at the 37th Annual Roth Conference","datePublished":"2025-03-05T14:28:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-present-at-the-37th-annual-roth-conference\/"},"wordCount":259,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-present-at-the-37th-annual-roth-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4ODg3MiM2NzkwMzYxIzIyMDcwNjA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-present-at-the-37th-annual-roth-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-present-at-the-37th-annual-roth-conference\/","name":"Longeveron\u00ae to Present at the 37th Annual Roth Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-present-at-the-37th-annual-roth-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-present-at-the-37th-annual-roth-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4ODg3MiM2NzkwMzYxIzIyMDcwNjA=","datePublished":"2025-03-05T14:28:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-present-at-the-37th-annual-roth-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-present-at-the-37th-annual-roth-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-present-at-the-37th-annual-roth-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4ODg3MiM2NzkwMzYxIzIyMDcwNjA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4ODg3MiM2NzkwMzYxIzIyMDcwNjA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-present-at-the-37th-annual-roth-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Longeveron\u00ae to Present at the 37th Annual Roth Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/822045","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=822045"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/822045\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=822045"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=822045"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=822045"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}